Cervical Cancer: Diagnosis and Treatment

Cervical cancer is a malignant tumor that develops in the area where the cervix meets the cervical canal, a narrow area adjacent to the vagina. The disease can be asymptomatic for a long time, and its early signs, such as bleeding and discomfort, often go unnoticed. The main cause of this pathology is a persistent infection caused by oncogenic types of the human papillomavirus. Timely consultation with a gynecologist ensures a high chance of a full recovery.

Modern medicine allows not only to successfully treat this disease in its early stages but also to effectively prevent it through screening and vaccination. Comprehensive diagnostics and personalized cancer treatment, including surgical, radiation, and drug treatments, are provided at the K+31 Clinic in Moscow using cutting-edge equipment and internationally recognized specialists.

Best
specialists
Expert
equipment
Advanced diagnostic
treatment
Sign up
Fill out the entry form on the page and we will call you back
Sign up Позвонить
Download the application “Personal Account K+31”
Everything about your health in one click!
Subscribe to social networks K+31
To keep up to date with current offers and receive useful advice about your health.

General information about the pathology

Cervical cancer, also known as cervical cancer, develops from abnormal changes in the cells of the cervical mucosa. Anatomically, this area connects the lower part of the uterus to the vagina. One of the characteristics of this area is the so-called transformation zone, or the area where glandular epithelial cells meet the stratified squamous epithelial cells of the vaginal portion of the cervix. It is in this zone that, in the vast majority of cases, the pathological process begins—the uncontrolled division of atypical cells, forming a neoplasm.

The vast majority of cases—over 95%—are directly linked to the persistence, or long-term survival, of highly oncogenic types of human papillomavirus (HPV), primarily types 16 and 18. HPV is a fairly common sexually transmitted infection, but the immune system often clears it on its own. However, with prolonged viral presence, its DNA can integrate into the cell genome, causing uncontrolled cell division and malignant transformation. This process is slow. On average, 10-15 years pass from infection and the appearance of early changes (dysplasia or cervical intraepithelial neoplasia) to the development of cancer.

According to the WHO, cervical cancer is the fourth most common cancer in women. This statistic underscores the social significance of the problem. Crucially, the disease can be prevented and managed, ensuring a favorable prognosis. The long precancerous period provides a unique window of opportunity for effective diagnosis and intervention.

The current strategy for combating cervical cancer is based on two key areas: primary prevention through HPV vaccination and secondary prevention through regular screening.

General information about the pathology

Classification and stages of cervical cancer

A classification system that takes into account the histological structure of the tumor and its extent in the body is used to determine patient management and prognosis.

Based on cellular structure, there are two main types of malignant cervical lesions:

  • Squamous cell carcinoma. It develops from the flat epithelial cells lining the vaginal portion of the cervix – the ectocervix. This type is the most common, accounting for up to 80-90% of all diagnosed cases.
  • Carcinoma. It develops from the mucus-producing glandular cells located in the cervical canal, affecting the endocervix. Cervical carcinoma is less common, but its incidence has been increasing in recent decades. This type also includes rarer forms: clear cell, mucinous, and others.

The stage of the pathology is determined according to the international FIGO classification based on the results of physical, instrumental, and morphological examinations. It reflects the anatomical distribution of the neoplasia.

  1. Stage 0 – preinvasive. Cancer cells are found only in the superficial layer of the epithelium, without invading the underlying tissue. This stage is also known as high-grade cervical intraepithelial neoplasia.
  2. Stage I. The tumor is limited to the cervix. Two substages are possible: IA: Microscopic invasion, detectable only histologically; IB: Clinically visible lesion, confined to the cervix.
  3. Stage II. The tumor extends beyond the uterus, involving the upper vagina or parametria, but does not reach the pelvic walls.
  4. Stage III. The pathological process affects the lower third of the vagina, the pelvic area, or leads to renal dysfunction.
  5. Stage IV. Characterized by the most extensive spread. There are two possible substages: IVA: Invasion of the mucosa of adjacent organs; IBB: Presence of distant metastatic lesions in the lungs, liver, bone tissue, and other organs.

Determining the FIGO staging system is necessary for choosing the optimal treatment plan, which may include both organ-preserving interventions in the early stages and radical surgery combined with combination therapy for advanced forms of the disease.

Diagnostic methods

Modern diagnostics are aimed not only at identifying the presence of a malignant process but also at determining its stage and morphological features. This comprehensive approach allows for a highly accurate diagnosis and the development of effective intervention strategies.

Screening and laboratory testing

Today, programs aimed at detecting the disease in apparently healthy women before any symptoms appear are actively used. Their fundamental goal is to detect precancerous changes and early, clinically asymptomatic forms of cancer, when treatment is most effective and the prognosis is favorable.

Two methods are used:

  • Cytology test (Pap test). During the analysis, cells collected from the surface of the cervix and cervical canal are examined under a microscope. A specialist evaluates their size, shape, and nuclear structure, identifying atypical elements.
  • HPV testing. Polymerase chain reaction (PCR) can identify the presence of oncogenic types of human papillomavirus (HPV) in the body, even at minimal concentrations. [The phrase "PAP" appears to be a mistranslation.]

The optimal strategy is to combine Pap and HPV testing, which significantly increases screening sensitivity and allows for the determination of further patient monitoring strategies.

Examination and Biopsy

If suspicious symptoms are present or the initial screening results are positive, the diagnosis moves into a more in-depth phase. The specialist performs a visual and manual assessment of the reproductive tract:

  • The texture and color of the cervical mucosa, as well as the presence of visible ulcers, growths, or areas of structural alteration, are assessed using a speculum.
  • A bimanual examination determines the size, shape, and mobility of the uterus, and identifies possible parametrial tissue compaction or tenderness.

If abnormalities are detected, the doctor prescribes a more extensive instrumental examination. A colposcopy is performed. This is a detailed examination of the cervix under significant optical magnification. The mucosa is treated with acetic acid and Lugol's solution. Healthy and abnormal tissues react to the reagents differently: atypical areas do not stain, but remain light. This indicates the need for a targeted biopsy with histological examination to verify the diagnosis.

Removing a small tissue sample from the most suspicious area allows the doctor to examine not only individual cells but also the tissue structure as a whole. Histological analysis provides a definitive answer regarding the presence or absence of invasive cancer, its type, and degree of differentiation.

Predisposing factors and underlying causes

The underlying cause of this pathology is HPV infection. Strains classified as highly oncogenic produce the oncoproteins E6 and E7. These proteins inactivate cellular defense mechanisms by suppressing the functions of the tumor suppressors p53 and pRb, ultimately leading to genomic instability, uncontrolled proliferation, and malignancy of epithelial cells. Although types 16 and 18 bear the primary pathogenic burden, other strains, such as 31, 33, and 45, are also responsible for some cases.

HPV infection is an important, but not the only, condition for the development of this pathology. Even the presence of the virus in combination with additional risk factors does not automatically lead to cancer. The vast majority of cases of infection are resolved by the body's own immune system. But even if the virus is detected, it's important not to panic and instead focus on regular monitoring by a specialist and lifestyle changes. This approach can significantly reduce potential risks.

The risk of developing pathology increases significantly with the combined influence of the following factors:

  • Tobacco smoking Carcinogenic resins have an affinity for the cervical epithelium. Traces of them are found in cervical mucus. They can enhance the negative effects of the virus, causing irreversible damage to cellular DNA and suppressing the local immune response, creating favorable conditions for the pathogen's proliferation
  • Long-term hormonal contraception Taking combined oral contraceptives for five or more years without medical supervision is associated with an increased risk of malignancy. It is believed that steroid hormones can modulate the expression of viral oncogenes and promote neoplastic transformation of infected cells
  • Early and active sexual activity with multiple partners These behavioral factors statistically increase the likelihood of infection with highly oncogenic HPV strains, creating a cumulative effect on the viral load and shortening the latency period for the development of precancerous lesions
  • Chronic immunosuppression Decreased immune reactivity observed in HIV infection, after organ transplantation, or while taking immunosuppressants disrupts natural control over viral activity, accelerating the transition from dysplasia to invasive neoplasm

Treatment of cervical cancer

When choosing a treatment strategy, the stage of the disease, the histological type of the tumor, the patient's age and fertility plans, and her overall medical condition are crucial. In most clinical situations, a combination approach is used, combining various techniques to achieve maximum antitumor efficacy.

Surgical methods

The extent of surgical intervention directly depends on the extent of the cancer. Modern gynecological oncology strives to perform organ-preserving surgeries in the early stages. The following may be performed:

  1. Cervical conization. A minimally invasive procedure during which a cone-shaped fragment of the cervix is ​​excised, including the cervical canal. It is used both for diagnostic purposes and as a standalone treatment for young women with preinvasive cancer and microinvasive carcinoma. It allows for the preservation of reproductive function.
  2. Tracheectomy. A complex organ-preserving procedure involving the removal of the cervix, parametrium, and upper vagina with the placement of a circular suture at the internal os. The uterine body is preserved and fixed in the pelvis. This method is indicated for stage IA2 and some stages IB1 in patients planning a pregnancy.
  3. Hysterectomy, or complete removal of the uterus. Standard surgical procedure for invasive cancer. Possible surgical options: simple – removal of the uterus and cervix; extended, or Wertheim-Meigs procedure – removal of the uterus and cervix, the upper third of the vagina, parametrium, pelvic tissue, and lymph nodes.

Radiation Therapy

Radiotherapy is a highly effective method that can be used either alone, for example, when surgery is contraindicated, or in combination with surgery and chemotherapy.

Two main forms of radiation are used:

  1. External beam radiation therapy. The radiation source is placed outside the patient's body. Modern techniques, such as IMRT (tomotherapy) and VMAT (volume-modulated arc therapy), allow for highly precise delivery of maximum doses to the target while minimizing impact on surrounding healthy organs.
  2. Intracavitary radiation therapy (brachytherapy). During the procedure, a radioactive source is inserted directly into the uterine cavity and vagina in close proximity to the tumor. This provides a powerful localized effect on the tumor.

The most effective treatment for locally advanced cancer is chemoradiation therapy—concurrent radiation and chemotherapy. This significantly increases tumor radiosensitivity and improves long-term outcomes.

Chemotherapy

The use of cytotoxic pharmacological agents solves several problems depending on the clinical situation:

  • Chemoradiation therapy uses moderate doses of drugs to sensitize tumor tissue to radiation.
  • Several courses of chemotherapy can be administered before surgery to reduce the volume of the primary tumor.
  • In metastatic or recurrent disease, systemic polychemotherapy becomes the primary method of palliative treatment, aimed at slowing disease progression, reducing symptoms, and prolonging life.

Rehabilitation measures

A comprehensive rehabilitation program begins immediately after completion of the main course of therapy. It is aimed at minimizing its consequences and returning you to a full life.

  1. Combating physical complications. This includes lymphedema therapy through specialized massage and compression hosiery, correction of premature menopause, and selection of non-hormonal therapy for urogenital disorders, as well as treatment of possible bladder and bowel dysfunction.
  2. Psychological support. Working with a psychologist helps overcome anxiety and fear of relapse, accept body changes, and improve quality of life.
  3. Dynamic monitoring. Lifelong monitoring includes regular gynecological examinations, Pap tests, HPV testing, ultrasound, and CT scans as indicated. Its goal is the timely detection and treatment of possible late complications of therapy and relapses.

General information

Symptoms of cervical cancer

The insidious nature of cervical cancer lies in its ability to develop for a long time without clinical symptoms. In the precancerous and early invasive stages, the disease is often discovered incidentally during a routine gynecological visit. As the tumor grows and invades underlying structures, symptoms begin to appear, requiring special attention.

The most characteristic signs of disease progression include:

  • Acyclic bleeding. The appearance of bleeding outside the menstrual cycle is a common reason to consult a doctor. So-called contact bleeding, which occurs after sexual intercourse, douching, or a gynecological examination, is considered a particularly worrisome indicator.
  • Changes in the nature of the discharge. As the tumor disintegrates, unusual discharge may appear: profuse, watery, blood-tinged, or brownish. In later stages, the discharge often acquires a foul odor due to infection and tissue necrosis.
  • Pain. The discomfort is usually localized in the sacrum, lumbar region, and lower abdomen. Its occurrence indicates involvement of the nerve plexuses, parametrium, or pelvic walls.
  • Signs from adjacent organs. When a tumor invades the bladder or intestines, symptoms of cystitis (frequent, painful urination) or proctitis (pain during defecation, tenesmus) develop. [The text appears to be incomplete and likely a mistranslation.]
  • General somatic disorders. Advanced cancer typically develops into cancer intoxication, which manifests as unexplained weakness, persistent weight loss, low-grade fever, anemia, and swelling of the lower extremities caused by impaired lymphatic drainage.

The occurrence of any of these complaints, especially after a prolonged absence of routine checkups, is an urgent reason for a thorough examination.

Consequences of the disease and side effects of therapy

The development of cancer and the antitumor treatment can lead to various disturbances in the body's functioning. These consequences are conventionally divided into two groups: those caused by the progression of the disease itself and those arising as a result of necessary treatment measures.

As the tumor grows and metastatic foci form, the functioning of the affected organs and systems is impaired. The following may occur:

  • Uronephrological disorders. When the process spreads to the parametrium and compresses the ureters, hydronephrosis develops – persistent dilation of the renal pelvis, leading to parenchymal atrophy and chronic renal failure.
  • Hematological abnormalities. Chronic blood loss from a disintegrating tumor triggers the development of anemia, which manifests as severe weakness, pallor, dizziness, and decreased exercise tolerance.
  • Pain syndrome. This occurs when the tumor invades the sacral nerve plexuses, pelvic bony structures, or when ureteral obstruction develops. The pain can become debilitating and constant.
  • Lymphostasis. Impaired lymphatic drainage due to blockage of pelvic lymph nodes by metastases leads to swelling of the lower extremities.

Treatment protocols in modern oncology are aimed at minimizing side effects, but completely avoiding them is not always possible.

Main consequences of surgical interventions:

  • Lymphocele – accumulation of lymph in the retroperitoneal space.
  • Bladder innervation disorder with the development of hypotension.
  • Risks of thromboembolic complications.
  • Adhesions in the pelvis.
  • Loss of reproductive function.
  • Premature menopause.

Reactions to radiation therapy can also be negative. Proctitis and cystitis, characterized by frequent, painful bowel movements and urination, can develop in the radiation area. A long-term consequence is parametrium fibrosis, which can worsen lymphedema and cause chronic pelvic pain.

The general toxicity of chemotherapy also plays a role. Cytostatic drugs affect all rapidly dividing cells, which can cause bone marrow suppression, alopecia, peripheral neuropathy, and ovarian dysfunction.

A comprehensive rehabilitation program, individually developed for each patient, can significantly mitigate these side effects and improve quality of life both during and after treatment.

Effectiveness of prevention and long-term prognosis

Treatment outcomes and patient prospects directly correlate with the stage of the disease at the start of therapy. Timely diagnosis and comprehensive prevention play a crucial role in the fight against this pathology.

The long-term prognosis is usually assessed by the five-year survival rate, which shows the percentage of patients who remain alive five years after diagnosis.

Survival rates by stage:

  • Preinvasive and microinvasive cancer - the rate approaches 98-100%
  • Localized forms - five-year survival is about 80-85%
  • Regional spread - the survival prognosis decreases to 40-60%
  • Metastatic disease - five-year survival does not exceed 15-20%

To reduce the risk of developing pathology, multi-level prevention is used, which Includes:

  1. Screening programs. Systematic HPV DNA testing in women aged 25 to 65 allows for the detection of changes and the initiation of interventions before invasive disease develops. Screening is recommended annually.
  2. Barrier contraception. Condom use reduces, but does not completely eliminate, the risk of HPV infection and also protects against other infections that potentially exacerbate carcinogenesis.

The Role of Immunization in Preventing Pathology

Vaccination is an effective primary prevention tool targeting the main etiologic factor of the disease.

Vaccines contain virus-like particles synthesized from the L1 capsid protein of the human papillomavirus. These particles do not contain the virus's genetic material and are completely safe, but they induce a strong immune response that prevents subsequent infection with oncogenic HPV types.

Immunization is most effective when administered before the onset of sexual activity, that is, before potential exposure to the virus. However, vaccination is also recommended for women before menopause.

Modern vaccines protect against the 7 most oncogenic HPV types, responsible for 90% of cancer cases, as well as against the types that cause genital warts. But it is important to remember that vaccination does not eliminate the need for regular screening tests.

Treatment Cost

The cost will depend on a number of clinical and organizational factors. The final cost is determined by a combination of necessary diagnostic, therapeutic, and rehabilitation measures, which are determined individually for each patient. It is influenced by the extent of the disease, the extent of the required intervention, the need for high-tech methods such as laparoscopic or robotic surgery, IMRT radiation therapy or targeted drugs, the length of hospitalization, and the subsequent rehabilitation course.

To obtain a detailed financial plan, an in-person consultation with a gynecologic oncologist is required. To schedule an appointment with specialists at the K+31 Clinic, please contact us at the number provided or submit a request.

Frequently asked questions from patients

Is cervical cancer hereditary?

No, unlike some other oncological diseases, this pathology does not have a direct hereditary predisposition. However, individual immune system characteristics, which may have a genetic component, influence the body's ability to resist the virus.

Can I have children after successful treatment?

Modern gynecologic oncology places great emphasis on preserving fertility. After early-stage organ-preserving surgeries, such as conization or trachelectomy, pregnancy and vaginal delivery are possible. The pregnancy management strategy in this case is determined by a consultation of oncologists and obstetricians/gynecologists.

How painful is a biopsy?

The biopsy procedure itself is usually well tolerated. The cervix has few pain receptors, so the sensation is often comparable to short-term discomfort or a slight pulling sensation in the lower abdomen. The doctor may use local anesthesia to completely eliminate any discomfort.

Does dysplasia need to be treated?

Dysplasia is considered a precancerous condition in which altered cells appear in the superficial layer of the cervix without growing deeper. It is not cancer, but it does require mandatory medical monitoring and, if indicated, active intervention.

What should you do if the disease returns?

The treatment approach for a relapse depends on its location and previous treatment. Options range from surgical removal of an isolated lesion to courses of chemotherapy, targeted therapy, or immunotherapy. In this situation, it is crucial not to despair and continue treatment with oncologists, who will prescribe a new treatment regimen.

Our doctors

Merkulov Igor Alexandrovich
Experience 34 years
Make an appointment
Merkulov
Igor Alexandrovich
Deputy Chief Physician for Oncology, Oncologist
Ershova Ksenia Igorevna
Experience 23 years
Make an appointment
Ershova
Ksenia Igorevna
Head of department, oncologist
Abashin Sergey Yuryevich
Experience 43 years
Make an appointment
Abashin
Sergey Yuryevich
Head of oncology projects, oncologist
Kalakutskaya Natalia Lvovna
Experience 28 years
Make an appointment
Kalakutskaya
Natalia Lvovna
Doctor-oncologist
Malygin Sergey Evgenyevich
Experience 31 year
Make an appointment
Malygin
Sergey Evgenyevich
Oncologist-mammologist, surgeon
Pshikhachev Ahmed Mukhamedovich
Experience 23 years
Make an appointment
Pshikhachev
Ahmed Mukhamedovich
Urologist, Oncologist
Shevchuk Alexei Sergeyevich
Experience 26 years
Make an appointment
Shevchuk
Alexei Sergeyevich
Oncogynecology consultant, obstetrician-gynecologist
Chichkanova Tatyana Vladimirovna
Experience 25 years
Make an appointment
Chichkanova
Tatyana Vladimirovna
Oncologist-mammologist, radiologist
Ovsiy Oksana Gennadievna
Experience 14 years
Make an appointment
Ovsiy
Oksana Gennadievna
Doctor-oncologist
Katz Ksenia Vladimirovna
Experience 12 years
Make an appointment
Katz
Ksenia Vladimirovna
Dermatovenerologist, oncologist
Korshikova Kamila Mukhtorovna
Experience 5 years
Make an appointment
Korshikova
Kamila Mukhtorovna
Radiotherapist
Ter-Arutyunyants Svetlana Andreevna
Experience 27 years
Make an appointment
Ter-Arutyunyants
Svetlana Andreevna
Radiotherapist, oncologist
Udin Oleg Ivanovich
Experience 32 years
Make an appointment
Udin
Oleg Ivanovich
Deputy chief physician for surgery, surgeon
Kogonia Lali Mikhailovna
Experience 52 years
Make an appointment
Kogonia
Lali Mikhailovna
Chemotherapist
Volkova Daria Mikhailovna
Experience 17 years
Make an appointment
Volkova
Daria Mikhailovna
Head of the Department of Radiation Therapy, Radiotherapist
Gomov
Mikhail Alexandrovich
Consultant in oncogynecology, obstetrician-gynecologist
Menkes (Ryabova) Yulia Alexandrovna
Experience 5 years
Make an appointment
Menkes (Ryabova)
Yulia Alexandrovna
Oncologist-chemotherapist
Grishin Igor Igorevich
Experience 33 years
Make an appointment
Grishin
Igor Igorevich
Obstetrician-gynecologist
Achba Maya Otarovna
Experience 18 years
Make an appointment
Achba
Maya Otarovna
Radiologist, ultrasound diagnostician, oncologist-mammologist
Lukyanenko Vladimir Alexandrovich
Experience 18 years
Make an appointment
Lukyanenko
Vladimir Alexandrovich
Oncologist-mammologist
Volenko Ivan Alexandrovich
Experience 15 years
Make an appointment
Volenko
Ivan Alexandrovich
Surgeon-oncologist-mammologist, plastic surgeon
Khailova Maria Sergeevna
Experience 5 years
Make an appointment
Khailova
Maria Sergeevna
Oncologist
Peshkova Marina Sergeevna
Experience 3 years
Make an appointment
Peshkova
Marina Sergeevna
Oncologist
Yakovleva Yana Sergeevna
Experience 8 years
Make an appointment
Yakovleva
Yana Sergeevna
Radiotherapist
Ivanova Olga Vladimirovna
Experience 26 years
Make an appointment
Ivanova
Olga Vladimirovna
Radiotherapist
Magdiev Arslan Khulatdaevich
Experience 14 years
Make an appointment
Magdiev
Arslan Khulatdaevich
Surgeon, oncologist, phlebologist
Morozova Albina Soslanovna
Experience 18 years
Make an appointment
Morozova
Albina Soslanovna
Acting head of the department of antitumor drug therapy, oncologist
Iluridze Georgy Davidovich
Experience 9 years
Make an appointment
Iluridze
Georgy Davidovich
Oncologist, traumatologist-orthopedist, surgeon
Alferov Anton Sergeevich
Experience 16 years
Make an appointment
Alferov
Anton Sergeevich
Leading urologist, andrologist
Gabaraev Alan Petrovich
Experience 13 years
Make an appointment
Gabaraev
Alan Petrovich
Urologist, andrologist
Balkarov Beslan Khasenovich
Experience 17 years
Make an appointment
Balkarov
Beslan Khasenovich
Surgeon, oncologist
Nemenov Alexander Alexandrovich
Experience 7 years
Make an appointment
Nemenov
Alexander Alexandrovich
Urologist, oncologist (oncourologist)
Melkonyan Lia Eduardovna
Experience 13 years
Make an appointment
Melkonyan
Lia Eduardovna
Oncologist, oncologist-mammologist, surgeon, radiologist, ultrasound diagnostician
Sokorutov Vasily Ivanovich
Experience 22 years
Make an appointment
Sokorutov
Vasily Ivanovich
Oncologist
Mashkey Maria Igorevna
Experience 2 years
Make an appointment
Mashkey
Maria Igorevna
Oncologist
All specialists
2GIS Award
2GIS Award

This award is given to clinics with the highest ratings according to user ratings, a large number of requests from this site, and in the absence of critical violations.

«Good place» according to Yandex
«Good place» according to Yandex

This award is given to clinics with the highest ratings according to user ratings. It means that the place is known, loved, and definitely worth visiting.

Our doctors are laureates of the ProDoctors Award
Our doctors are laureates of the ProDoctors Award

The ProDoctors portal collected 500 thousand reviews, compiled a rating of doctors based on them and awarded the best. We are proud that our doctors are among those awarded.

Make an appointment at a convenient time on the nearest date

News

20 june 2025 year
Possibilities of re-irradiation in case of recurrent glioblastoma
Author: Volkova Daria Mikhailovna, radiotherapist, head of the radiation therapy department of K31 City.
22 january 2025 year
Briefly about sarcomas in patients with Lynch syndrome
Khailova Maria Sergeevna, oncologist, Department of Antitumor Drug Therapy, K31 City.
17 january 2025 year
Perspective: More than a conference

Our head of the radiation therapy department, Daria Mikhailovna Volkova, recently returned from the conference "Prospect is more than a conference" in Kazan. There she represented our clinic K+31, sharing her experience and knowledge.

At the conference, Daria Mikhailovna gave a report on the topic: "Clinical case of CRT in unresectable NSCLC".

27 december 2024 year
A new approach to the treatment of soft tissue sarcomas
Sarcomas are a rare and heterogeneous group of malignant tumors: less than 1% of all malignant neoplasms in adults. Such a rare occurrence of this nosology makes it difficult to conduct large-scale studies, so each positive result of scientific work is worth its weight in gold.
17 december 2024 year
Ipilimumab with nivolumab in molecularly selected patients with castration-resistant prostate cancer
Metastatic castration-resistant prostate cancer (mCRPC) is commonly resistant to immune checkpoint inhibitors (ICIs).
01 december 2024 year
Results of the round table K+31 West “Non-oncological problems of cancer patients”
The K+31 West Clinic held a scientific and practical conference that brought together leading experts in the field of oncology, gynecology, radiotherapy, cardiology and other areas. The event discussed modern approaches to the diagnosis and treatment of oncological diseases, as well as issues of interdisciplinary interaction.
29 november 2024 year
177Lu-PSMA-617 versus androgen axis inhibitor in the treatment of taxane-naïve advanced metastatic castration-resistant prostate cancer
Prostate-specific membrane antigen (PSMA) is a well-studied cell membrane antigen specific for prostate cancer (PCa) and is not found in other tissues of the body.
09 november 2024 year
Are the long-term oncologic outcomes different between neoadjuvant chemotherapy and adjuvant chemotherapy in locally advanced breast cancer?
Today's post is prompted by the question: "Is there a difference in cancer outcomes depending on the sequence of chemotherapy and surgery?"
26 october 2024 year
Neoadjuvant therapy with nivolumab + relatlimab or nivolumab + ipilimumab in triple-negative breast cancer
In triple-negative breast cancer (TNBC), the addition of immunotherapy to neoadjuvant chemotherapy improves pathological complete response (pCR) rates...
13 october 2024 year
Breakthrough in oncology: treatment of metastatic melanoma with the drug "Nurdati"
Recently, a young patient with a relapse of metastatic melanoma came to the K+31 West clinic. After successful remission on targeted drugs, the disease made itself felt again. An important task arose - to choose a new approach to treatment...
07 october 2024 year
The influence of progesterone receptor levels on prognosis in patients with advanced breast cancer
A CDK4/6 inhibitor in combination with endocrine therapy is the standard first-line therapy for patients with advanced hormone-receptor-positive (HR) breast cancer...
07 october 2024 year
VII International Forum of Oncology and Radiotherapy “For Life – For Life”
The forum is a significant event in the oncology industry, the oncologist, radiotherapist of the K+31 Clinic - Svetlana Andreevna Ter-Arutyunyants spoke.
27 september 2024 year
Hematological toxicity of chemotherapy in patients with breast and ovarian cancer
BRCA1 and BRCA2 are tumor suppressor genes that play a central role in repairing double-stranded DNA breaks through homologous recombination, a fundamental DNA repair process that maintains genome integrity and, in particular, prevents possible tumor transformation of cells. Defects and mutations in these genes significantly increase the risk of developing cancer of various organs. According to some data, the prevalence of pathogenic variants in these genes in the Russian population is 1:300 for the BRCA1 gene and 1:800 for the BRCA2 gene.
17 september 2024 year
Real-World Outcomes of Lenvatinib and Anti-PD-1 Therapy in Patients With Advanced Melanoma
There are currently no treatment options for patients with advanced melanoma who have failed immunotherapy or targeted therapy.
20 august 2024 year
K+31 West held a special excursion for high school students from the “First Movement” together with RUDN University
Our future doctors saw the international level of medical services, looked into the radiology department, where cancer is treated according to world standards, and learned about advanced diagnostic methods.
15 august 2024 year
Preoperative iron supplementation is better for treating iron deficiency anemia
Iron administration is associated with a significant reduction in 30-day postoperative mortality and morbidity compared with red blood cell transfusion
11 august 2024 year
How to apply for oncology treatment under compulsory medical insurance in Moscow: instructions
According to Russian law, citizens of the country can receive medical care in the event of detection of an oncological disease at the expense of the compulsory medical insurance, and patients from the regions can apply for treatment in Moscow.
07 august 2024 year
Oncology news digest 04.08.2024
Amivantamab plus Lasertinib versus Osimertinib for first-line treatment of EGFR-mutated advanced NSCLC.
04 august 2024 year
Oncology news digest 07/21/2024

Long-term results of adjuvant therapy with dabrafenib and trametinib in stage III melanoma. COMBI-AD study.

21 july 2024 year
Oncology news digest 07/07/2024
Neoadjuvant nivolumab and ipilimumab for resectable stage III melanoma
07 july 2024 year
Oncology news digest 30.06.2024
A randomized, double-blind, placebo-controlled, phase II trial of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.
30 june 2024 year
Effect of Omega-3 Fatty Acid Diet on Prostate Cancer Progression
Involvement of tumor-associated macrophages and GPR120 dependence in the tumor microenvironment.
27 june 2024 year
The right to quality of life: K+31 hosted a round table for doctors on pain management in cancer patients

Top experts from K+31 and other clinics discussed a personalized approach to the assessment and treatment of pain in cancer patients.

29 may 2024 year
Obesity and the risk of developing cancer: what is the impact of body mass index, risks and features

Obesity is a chronic disease characterized by excessive accumulation of fatty tissue in the body.

15 march 2024 year
Thyroid cancer: types, symptoms, treatment methods

Formations (so-called nodes) in the thyroid gland are often benign in nature, however, they require regular monitoring. It is important to carry out additional studies in a timely manner (including a biopsy of suspicious nodes) in order to diagnose cancer in a timely manner. process and begin appropriate treatment.

14 march 2024 year
How to diagnose pancreatic cancer in the early stages: first symptoms and diagnostic methods

Oncopathology of this type is complicated by the location of the affected organ. Carrying out the operation requires high qualifications specialist and is often dangerous to the patient’s health. In addition, it is difficult to diagnose the disease at an early stage. not always, since the pathology develops over many years asymptomatically, and the appearance of the first signs may already indicate stage 3 or 4.

05 march 2024 year
Malignant bone tumors - symptoms, diagnosis, modern methods of therapy

Bone tumor is a collective name for malignant and benign tumors that affect skeletal bone tissue (bone or cartilage). Malignant bone tumors are called sarcomas.

02 march 2024 year
What is epidural anesthesia?

This type of anesthesia has become widely known due to its use in obstetrics and gynecology, as it is widely used to facilitate labor.

01 march 2024 year
Stomach cancer: symptoms, modern methods of diagnosis and therapy

In order to timely detect and effectively eliminate oncological pathology, it is recommended to undergo regular examinations and be observed by specialists if there is discomfort in the gastrointestinal tract.

14 february 2024 year

Price

Reception
Price
Primary oncologist appointment
from 5 900 ₽
Repeated appointment with an oncologist
from 5 900 ₽

To get a consultation

Fill out the form, our managers will contact you within 15 minutes

Reviews

I want to thank the doctor for the professional operation. Everything went smoothly, carefully, and without unnecessary stress. The doctor explained each step in detail and was always available during the recovery period. His very attentive and humane attitude is especially valuable.
26.01.2026
K. Alan Vladimirovich

About doctor:

Gabaraev Alan Petrovich

a great doctor with golden hands!
21.01.2026
G. Olga Alexandrovna
Akhmedkhan Mukhamedovich masterfully performed a renal cell carcinoma resection. A modest, wonderful man.
15.01.2026
B. Vitaly Vladimirovich
No words needed, the ratings speak for themselves. A magnificent doctor and a wonderful person.
15.01.2026
B. Vitaly Vladimirovich
A huge thank you to Anton Sergeevich Alferov for his attention to his patients. He is a true professional.
14.01.2026
Olga

About doctor:

Alferov Anton Sergeevich

Good and responsive doctor!
29.12.2025
S. Irina Viktorovna

About doctor:

Melkonyan Lia Eduardovna

Every visit is comfortable
19.12.2025
R. Elizaveta Alexandrovna

About doctor:

Achba Maya Otarovna

Maya Otarovna is a very attentive doctor. She explained everything thoroughly and expertly and answered all my questions. Thank you for your advice, patience, and attention.
17.12.2025
B. Natalia Ivanovna

About doctor:

Achba Maya Otarovna

Competent, explained clearly, gave recommendations for further treatment
16.12.2025
Ch. Valery Vasilievich
Very sweet, she helped me!!!
14.12.2025
I. Khamisa Nasrulaevna

About doctor:

Katz Ksenia Vladimirovna

Почему К+31?
К + 31 — full-cycle multidisciplinary medical centers, including the possibility of providing medical services of European quality level.
К + 31 — are leading doctors and diagnostics using high-tech equipment from world manufacturers (Karl Storz, Olympus, Siemens, Toshiba, Bausch&Lomb, Technolas, Zeiss, Topcon).
К + 31 — is ethical. The staff of K+31 clinics maintain open relationships with patients and partners. An individual approach to each patient is the basis of our service standards.
К + 31 — is modernity. On call 24/7: call center operators will answer your questions at any time and book you an appointment with doctors. Contact us by phone, through the feedback form on the website and Max.

Our clinics

K+31 on Lobachevskogo

st. Lobachevskogo, 42/4

+7 499 999-31-31

Subway
1
11
Prospect Vernadsky Station
By a car
Lobachevsky, we pass the first barrier (security post of the City Clinical Hospital No. 31), turn right at the second barrier (security post K+31)
Parking pass
Opening hours
Mon-Fri: 08:00 – 21:00
Saturday: 09:00 – 19:00
Sunday: 09:00 – 18:00
K+31 Petrovskie Vorota

1st Kolobovsky pereulok, 4

74999993131

Subway
9
Tsvetnoy Bulvar
10
Trubnaya
By a car
Moving along Petrovsky Boulevard, turn onto st. Petrovka, right after - on the 1st Kolobovsky per. Municipal parking
Opening hours
Mon-Fri: 08:00 – 21:00
Sat-Sun: 09:00 – 19:00
K+31 West

Orshanskaya, 16/2; Ak. Pavlova, 22

74999993131

Subway
3
Molodezhnaya
By a car
Moving along Orshanskaya street, we turn to the barrier with the guard post K+31. You do not need to order a pass, they will open it for you
Opening hours
Mon-Fri: 08:00 – 21:00
Sat-Sun: 09:00 – 18:00
Didn't find the service you were looking for?

Экстренная помощь